1. Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?
- Author
-
Amélie Lopès, Elisabeth Billard, Romain Villeger, Guillaume Carrier, Nicolas Barnich, Johan Gagnière, Mathilde Bonnet, Julie Veziant, Emilie Vazeille, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Sanofi [Vitry-sur-Seine], SANOFI Recherche, Institut du Cancer de Montpellier (ICM), CHU Clermont-Ferrand, Ministere de la Recherche et de la Technologie Universite Clermont-Auvergne UMR1071INRA USC-2018Ligue nationale contre le cancerFrench government IDEX-ISITE initiative of the University of Clermont Auvergne 16-IDEX-0001-CAP 20-25CIFRE grant 2015/622CPER EPICURE 2016 Institut National de la Sante et de la Recherche Medicale (Inserm), OUERTANI, jeannette, and ANR-16-IDEX-0001,CAP 20-25,CAP 20-25(2016)
- Subjects
intestinal microbiota ,0301 basic medicine ,Colorectal cancer ,medicine.medical_treatment ,Antibiotics ,anticancer treatment ,microbiome ,Review ,Gut flora ,[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology ,chemotherapy ,lcsh:Chemistry ,surgery ,0302 clinical medicine ,Neoplasms ,lcsh:QH301-705.5 ,Spectroscopy ,biology ,General Medicine ,Prognosis ,Combined Modality Therapy ,3. Good health ,Computer Science Applications ,Treatment Outcome ,030220 oncology & carcinogenesis ,Adjuvant ,medicine.drug_class ,Catalysis ,Inorganic Chemistry ,03 medical and health sciences ,medicine ,Animals ,Humans ,cancer ,Microbiome ,Physical and Theoretical Chemistry ,Molecular Biology ,radiotherapy ,business.industry ,Organic Chemistry ,Cancer ,[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology ,Immunotherapy ,medicine.disease ,biology.organism_classification ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,Gastrointestinal Microbiome ,Radiation therapy ,030104 developmental biology ,lcsh:Biology (General) ,lcsh:QD1-999 ,probiotics ,Cancer research ,[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,adjuvant therapies ,business - Abstract
International audience; Recently, preclinical and clinical studies targeting several types of cancer strongly supported the key role of the gut microbiota in the modulation of host response to anti-tumoral therapies such as chemotherapy, immunotherapy, radiotherapy and even surgery. Intestinal microbiome has been shown to participate in the resistance to a wide range of anticancer treatments by direct interaction with the treatment or by indirectly stimulating host response through immunomodulation. Interestingly, these effects were described on colorectal cancer but also in other types of malignancies. In addition to their role in therapy efficacy, gut microbiota could also impact side effects induced by anticancer treatments. In the first part of this review, we summarized the role of the gut microbiome on the efficacy and side effects of various anticancer treatments and underlying mechanisms. In the second part, we described the new microbiota-targeting strategies, such as probiotics and prebiotics, antibiotics, fecal microbiota transplantation and physical activity, which could be effective adjuvant therapies developed in order to improve anticancer therapeutic efficiency.
- Published
- 2019
- Full Text
- View/download PDF